Seeking Alpha

Nektar Therapeutics (NKTR) agrees to sell royalties for its Cimzia and Mircera drugs to Royalty...

Nektar Therapeutics (NKTR) agrees to sell royalties for its Cimzia and Mircera drugs to Royalty Pharma for $124M. The company plans to use the net proceeds of the transaction towards the repayment of its $215M in convertible debt. Shares are currently under a trading halt.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs